Influence of oral contraceptives on the incidence of premalignant and malignant lesions of the cervix.
The effect of oral contraceptive use on the development of severe dysplasia, carcinoma in situ and invasive carcinoma of the cervix was studied by a prospective longitudinal survey of 32,000 women. They were enrolled into the study between the ages of 15 and 39. Some had started oral contraceptive use before enrollment, others started after enrollment and some remained non-users throughout the study period. They were followed-up to 6-1/2 years. Analyses were performed on data from 24,784 women who met our criteria for incidence. Data were adjusted for years of follow-up, age at enrollment, age at first pregnancy, number of pregnancies, number of smears, and duration of use.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002277:Carcinoma / Q000139:chemically induced*; D002278:Carcinoma in Situ / Q000139:chemically induced*; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000009:adverse effects; D008572:Menarche; D008656:Mestranol / Q000009:adverse effects; D009640:Norethindrone / Q000009:adverse effects; D010298:Parity; D011446:Prospective Studies; D013997:Time Factors; D002578:Uterine Cervical Dysplasia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced*; D015022:Yugoslavia
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol; D008656:Mestranol; D008234:Lynestrenol; D009640:Norethindrone